• Mubritinib (TAK 165): Benchmark HER2 and OXPHOS Inhibitor...

  2026-03-21

  Mubritinib (TAK 165) is a selective mitochondrial complex I and HER2/ErbB2 inhibitor with high potency in acute myeloid leukemia (AML) and Kaposi’s sarcoma-associated herpesvirus (KSHV) models. Its dual-action mechanism enables precision targeting in chemotherapy-resistant cancer and orthopoxvirus studies.

• Mubritinib (TAK 165): Mitochondrial Complex I Inhibitor f...

  2026-03-20

  Mubritinib (TAK 165) is a potent mitochondrial electron transport chain complex I inhibitor with selective cytotoxicity in chemotherapy-resistant AML and KSHV-positive PEL cells. Its unique mechanism, distinct from classical HER2 inhibition, enables targeted disruption of oxidative phosphorylation, providing a valuable tool for advanced cancer and virology research.

• Mubritinib (TAK 165): Selective Mitochondrial Complex I I...

  2026-03-20

  Mubritinib (TAK 165) is a potent, selective mitochondrial electron transport chain complex I inhibitor. It demonstrates nanomolar cytotoxicity in acute myeloid leukemia (AML) and primary effusion lymphoma (PEL) cells, with minimal activity against normal hematopoietic stem cells. Mubritinib’s primary research value is in targeting oxidative phosphorylation and overcoming chemotherapy resistance in cancer models.

• Mubritinib (TAK 165): From HER2 Inhibition to Mitochondri...

  2026-03-19

  This thought-leadership article reframes Mubritinib (TAK 165) as more than a selective HER2/ErbB2 inhibitor, delving into its emerging role as a mitochondrial complex I inhibitor for tackling chemotherapy-resistant acute myeloid leukemia (AML), primary effusion lymphoma (PEL), and orthopoxvirus infections. Integrating mechanistic insight, experimental benchmarks, and forward-looking guidance, we outline how translational researchers can leverage Mubritinib’s unique properties—exclusively supplied by APExBIO—to accelerate breakthroughs in cancer metabolism and antiviral strategies. By synthesizing evidence from recent in vitro studies and scenario-driven optimization guides, this article charts new directions for experimental design and precision therapy development.

• Mubritinib (TAK 165): Mechanistic Advances and Strategic ...

  2026-03-19

  Mubritinib (TAK 165) is redefining the paradigm of targeted cancer therapy research by bridging mitochondrial metabolism, HER2-driven oncogenesis, and viral oncology. This thought-leadership article unpacks the latest mechanistic insights—leveraging recent molecular pharmacology findings—and delivers actionable strategies for translational researchers committed to overcoming chemotherapy resistance in acute myeloid leukemia (AML), primary effusion lymphoma (PEL), and beyond. Discover how Mubritinib’s dual inhibition of HER2 and mitochondrial complex I, in tandem with its unique protein-binding properties, is shaping the future of precision oncology.

• Beyond HER2: Mubritinib (TAK 165) and the Mitochondrial R...

  2026-03-18

  Mubritinib (TAK 165) is redefining the landscape of targeted cancer and viral therapy. Originally classified as a selective HER2/ErbB2 inhibitor, emerging research reveals its potent and clinically relevant activity as a mitochondrial complex I inhibitor. This thought-leadership article equips translational researchers with advanced mechanistic insights, strategic experimental guidance, and a future-focused perspective—emphasizing Mubritinib's dual-action profile in chemotherapy-resistant cancers and viral oncology, recent breakthroughs in mitochondrial targeting, and actionable protocols for integrating this compound into next-generation research workflows.

• Scenario-Driven Solutions: Mubritinib (TAK 165) for Repro...

  2026-03-18

  This article provides a practical, scenario-driven guide for deploying Mubritinib (TAK 165) (SKU B1543) in cell viability, proliferation, and cytotoxicity assays. Through evidence-based Q&A, we address real laboratory challenges, highlight best practices, and demonstrate how Mubritinib’s mitochondrial complex I inhibition enables sensitive, selective, and reproducible research workflows.

• Mubritinib (TAK 165): Data-Driven Solutions for Reliable ...

  2026-03-17

  This article addresses real laboratory challenges in cell viability, proliferation, and cytotoxicity assays, showcasing how Mubritinib (TAK 165) (SKU B1543) from APExBIO ensures reproducibility and selectivity, especially in chemotherapy-resistant AML and PEL models. Through scenario-based Q&A, researchers gain actionable insights into optimal assay design, data interpretation, and vendor selection, all firmly grounded in published data and validated workflows.

• Mubritinib (TAK 165): Mitochondrial Complex I Inhibition ...

  2026-03-17

  Explore the multifaceted role of Mubritinib (TAK 165) as a mitochondrial electron transport chain complex I inhibitor in cancer biology and antiviral research. This article uncovers new mechanistic insights and applications—distinct from conventional HER2-focused narratives—positioning Mubritinib as a cornerstone for targeted cancer therapy research.

• Mubritinib (TAK 165): Selective Complex I Inhibitor for C...

  2026-03-16

  Mubritinib (TAK 165) is a selective mitochondrial electron transport chain complex I inhibitor with potent cytotoxicity against chemotherapy-resistant AML and KSHV-associated PEL cells. While initially classified as a HER2 inhibitor, its HER2 activity is not clinically relevant in most cancer contexts. This dossier details Mubritinib’s mechanisms, benchmarks, and optimal application parameters for targeted cancer research.

• Mubritinib (TAK 165): Selective Mitochondrial Complex I I...

  2026-03-16

  Mubritinib (TAK 165) is a potent and selective inhibitor of mitochondrial electron transport chain complex I, with demonstrated efficacy against chemotherapy-resistant acute myeloid leukemia (AML) and Kaposi's sarcoma-associated herpesvirus-positive lymphomas. The compound exerts its effects through oxidative phosphorylation inhibition and apoptosis induction, not clinically relevant HER2 blockade. This article synthesizes the latest mechanistic, benchmarking, and workflow integration data for translational cancer biology.

• Mubritinib (TAK 165): Selective Mitochondrial Complex I I...

  2026-03-15

  Mubritinib (TAK 165) is a potent mitochondrial electron transport chain complex I inhibitor with robust selectivity and efficacy in chemotherapy-resistant acute myeloid leukemia (AML) and Kaposi’s sarcoma-associated herpesvirus (KSHV)-positive primary effusion lymphoma (PEL) models. This article provides a machine-readable, evidence-grounded overview of its biological rationale, mechanism, and research applications.

• Mubritinib (TAK 165): Precision Complex I Inhibition for ...

  2026-03-14

  Mubritinib (TAK 165) is a potent mitochondrial complex I inhibitor with high selectivity for chemotherapy-resistant AML and primary effusion lymphoma models. It offers unique mechanistic insights and workflow flexibility for targeted cancer and antiviral research, as evidenced by recent peer-reviewed studies.

• Mubritinib (TAK 165): Advanced Workflows for Complex I an...

  2026-03-13

  Mubritinib (TAK 165) is transforming targeted cancer therapy and virology research through its dual inhibition of mitochondrial complex I and HER2/ErbB2 pathways. This guide details optimized experimental workflows, advanced troubleshooting tactics, and innovative applications in chemotherapy-resistant AML, PEL, and orthopoxvirus studies—empowering researchers to harness Mubritinib’s full potential.

• Mubritinib (TAK 165): Selective Mitochondrial Complex I I...

  2026-03-13

  Mubritinib (TAK 165) is a potent mitochondrial electron transport chain complex I inhibitor with demonstrated selectivity for chemotherapy-resistant AML and KSHV-positive lymphoma cells. Its efficacy extends beyond HER2 pathway inhibition, offering novel approaches for targeted cancer therapy and antiviral research.

451 records 24/31 page Previous Next First page 上5页 2122232425 下5页 Last page